| Management target | Net Profit 50.0% FY27 |
|---|
| Revenue growth | Q2 +16.2% YoY, +4.4% QoQ; H1 +17.8%. |
|---|---|
| Margins | Q2 EBITDA margin 21.1% vs 22.1% YoY; H1 up to 21.3%. |
| Demand visibility | API H2 visibility strong; animal health guided 20%+ growth. |
| Management confidence | Upbeat; 'strong' repeated, hedged on US and human health. |
Growth
Q2 revenue +16.2% YoY and +4.4% QoQ; H1 +17.8%. US sales fell YoY against a one-off exclusivity quarter last year.
Outlook
Guides PAT growth above 50% in FY27 (H1 +49%). Capex ~₹150 Cr over two years. ₹20 Cr loan prepayment considered; Europe launch next year.
Risks
Q2 gross margin 53.7% vs 55.5%. Q2 ESOP cost ~₹42 Cr, with ~₹40 Cr/quarter expected. Human health launches delayed; 2029-30 pipeline unproven.
Last quarter's promises, checked
Delivered
- Rev growth 13-15% → H1 +17.8% (= BEAT)
- API growth 13-14% → Q2 API ~20% (= BEAT)
- BFL close in 2-3 mths → acquired (= BEAT)
Partly delivered
- EBITDA margin 20-22% → Q2 21.1%, down from 22.1% (= PARTIAL)
- Animal Health 20%+ → companion ~60%; total n/a (= PARTIAL)
Missed
- Capex ₹250-300Cr/yr → ~₹150Cr over 2 yrs (= MISS)
- Q2 ESOP ₹40Cr → ₹42Cr (= MISS)
- 1-2 Human launches FY27 → delayed (= MISS)
Earnings Call Transcript filed with NSE, NSE: VIYASH. Summary written with AI assistance from the document.
Viyash Scientific Ltd: key numbers
- Share price
- ₹233.36
- Market cap
- ₹10,314 Cr
- Revenue (annual)
- ₹3,420 Cr
- Net profit (annual)
- ₹177.3 Cr
- P/E (TTM)
- 44.4×Sector 49.0×
- Promoter holding
- 49.24%-12.07% QoQ
- FII holding
- 2.60%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Viyash Scientific Ltd
All →Viyash Scientific Employee Stock Options
Viyash Scientific allotted 67,893 shares under two ESOP schemes at Rs 86 and Rs 101 exercise prices. Paid-up capital rises to Rs 88.41 Crore.
Viyash Scientific Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹987.9 Cr (+16.2%), EBITDA ₹207.7 Cr (+10.3%, 21.0% margin), PAT ₹84.7 Cr (+16.1%). H1 PAT ₹163.9 Cr (+49.4%). BioForLife Italy acquisition completed.
Viyash Scientific Results Update
Viyash Scientific's Q2 FY27 press release shows H1 revenue up 17.8% and PAT up 49%. An earnings call is scheduled for 14 November 2026.
Viyash Scientific Q2 FY27 Results: Net Profit ₹84.7 Cr, Up 16.2% YoY
Viyash Scientific Ltd filed unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026. Standalone revenue from operations was INR 3,906.50 million for the quarter.
- Key figure
- Net profit ₹84.7 Cr · +16.2% YoY
Viyash Scientific Employee Stock Options
Viyash Scientific allotted 228,408 shares under two employee stock option schemes. Paid-up capital rose to 44,19,91,958 shares of Rs.2 each.
Viyash Scientific Board Meeting Date
Viyash Scientific will hold a board meeting on 13 November 2026 to consider unaudited quarterly and half-yearly results. The trading window remains closed until 15 November 2026.